OncoSec Medical Gets a Buy Rating from Maxim Group

By Ryan Adsit

Maxim Group analyst Jason McCarthy reiterated a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $5. The company’s shares opened today at $0.97, close to its 52-week low of $0.94.

McCarthy observed:

“Oncosec’s PISCES study (IL-12 + Keytruda) prepares to launch in June. Merck (MRK – $63.00 – NR) will supply Keytruda on an investigational basis to support the study.”

According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -11.5% and a 36.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ImmunoCellular Therapeutics, Mateon Therapeutics Inc, and Stellar Biotechnologies.

Currently, the analyst consensus on OncoSec Medical is Strong Buy and the average price target is $5.50, representing a 467.0% upside.

In a report issued on May 10, Noble Financial also reiterated a Buy rating on the stock.

Based on OncoSec Medical’s latest earnings report for the quarter ending January 31, the company posted quarterly revenue of $0 and GAAP net loss of $5.39 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $6.25 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in designing, developing and commercializing medical products for the treatment of cancer. It engages in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered in San Diego, CA.

  • Loki

    Jason, you may want to kill yourself. You do stocks more harm than good with your analysis…